Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
51
CLCS Quote, Financials, Valuation and Earnings
Last price:
$0.8500
Seasonality move
:
14.35%
Day range:
$0.8500 - $0.8500
52-week range:
$0.1819 - $0.9899
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
12
Avg. volume:
5.6K
1-year change:
112.5%
Market cap:
$38.3M
Revenue:
--
EPS (TTM):
-$0.15
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Cell Source, Inc. has -- downside to fair value with a price target of -- per share.
CLCS vs. S&P 500
-
Over the past 5 trading days, Cell Source, Inc. has underperformed the S&P 500 by -0.38% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cell Source, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cell Source, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Cell Source, Inc. reported revenues of --.
Earnings Growth
-
Cell Source, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Cell Source, Inc. reported earnings per share of -$0.04.
Enterprise value:
48.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-17.99x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$4.2M | -$4.2M | -$3.8M | -$866.4K | -$685.1K | |
| EBITDA | -$4.2M | -$4.2M | -$3.8M | -$866.4K | -$685.1K | |
| Diluted EPS | -$0.18 | -$0.17 | -$0.15 | -$0.04 | -$0.02 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $452.3K | $313.8K | $409.8K | $195.2K | $286.5K | |
| Total Assets | $452.3K | $313.8K | $409.8K | $195.2K | $286.5K | |
| Current Liabilities | $8.4M | $10.1M | $13M | $15.8M | $19.1M | |
| Total Liabilities | $8.4M | $10.1M | $13M | $15.8M | $19.1M | |
| Total Equity | -$7.9M | -$9.8M | -$12.6M | -$15.6M | -$18.8M | |
| Total Debt | $3.6M | $5.6M | $7M | $8.4M | $8.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$3.1M | -$2.3M | -$2.7M | -$722.3K | -$748.3K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $3.3M | $2.1M | $2.7M | $741.9K | $800K | |
| Free Cash Flow | -$3.1M | -$2.3M | -$2.7M | -$722.3K | -$748.3K | |
CLCS
Sector
Market Cap
$38.3M
$25.2M
Price % of 52-Week High
85.87%
49.83%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.77%
1-Year Price Total Return
112.5%
-21.9%
Beta (5-Year)
-225.097
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.8416
200-day SMA
Buy
Level
$0.4392
Bollinger Bands (100)
Buy
Level
0.3313 - 0.7313
Chaikin Money Flow
Buy
Level
14K
20-day SMA
Sell
Level
$0.8708
Relative Strength Index (RSI14)
Buy
Level
58.5347
ADX Line
Sell
Level
41.5517
Williams %R
Neutral
Level
-28.7522
50-day SMA
Buy
Level
$0.6804
MACD (12, 26)
Buy
Level
0.1959
25-day Aroon Oscillator
Sell
Level
-8
On Balance Volume
Sell
Level
-2.6K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-349.5015)
Sell
CA Score
(Annual)
Level (-402.7495)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (548.9278)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cell Source, Inc. is a biotechnology company, which focuses on developing cell therapy treatments based on the management of immune tolerance. Its Veto Cell immune system management technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. The Veto Cell platform roadmap consists of two main programs: VETO CAR-T (with and without HSCT) and Veto Cell Organ Transplantation. The company was founded on June 6, 2012 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, CLCS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLCS average analyst price target in the past 3 months is --.
-
Where Will Cell Source, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cell Source, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Cell Source, Inc.?
Analysts are divided on their view about Cell Source, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cell Source, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Cell Source, Inc.'s Price Target?
The price target for Cell Source, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CLCS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cell Source, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CLCS?
You can purchase shares of Cell Source, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cell Source, Inc. shares.
-
What Is The Cell Source, Inc. Share Price Today?
Cell Source, Inc. was last trading at $0.8500 per share. This represents the most recent stock quote for Cell Source, Inc.. Yesterday, Cell Source, Inc. closed at $0.8500 per share.
-
How To Buy Cell Source, Inc. Stock Online?
In order to purchase Cell Source, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CLCS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CLCS
Sector
P/E ratio
--
23.30x
PEG ratio
--
-0.01x
P/B ratio
--
1.78x
Price / LTM sales
--
1.55x
Growth Metrics
CLCS
Sector
Revenue growth
--
3.69%
Earnings growth
--
9.95%
Revenue (5-year growth)
--
6.38%
Earnings forecast
--
-$0.19
Profitability
CLCS
Sector
Profitability FY 2024
--
$2.6M
Return on invested capital
--
-33.25%
Return on assets
--
-29.67%
Return on equity
--
-38.66%
Earnings Date
Last Earnings Date
Feb
20
Next Earnings Date
Feb
20
Estimated Next Earnings Date
May
22
Balance Sheet
CLCS
Sector
Total cash
$23K
$25.1M
Short term investments
--
$24M
Total assets
$286.5K
$72.5M
Long term debt
--
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 2.39% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 0.05% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is up 0.46% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
